-
公开(公告)号：EP1368376A2
公开(公告)日：2003-12-10
申请号：EP02719729.2
申请日：2002-01-25
发明人： BEUG, Hartmut , HOFMANN, Johannes
CPC分类号： C07K14/4747 , A61K38/00 , C12N2799/027
摘要： The invention provides a novel proapoptotic inducer protein 'p12', that was identified in myeloid/erythroid cytokine dependent cells, and DNA molecules encoding it. The p12 protein and DNA molecules are useful for therapy and diagnosis of conditions which are associated with a deregulated apoptosis pathway and for screening compounds that modulate p12 activity.
-
公开(公告)号：EP0716689B1
公开(公告)日：2002-10-02
申请号：EP95925778.3
申请日：1995-06-28
CPC分类号： C12N5/0641 , C12N2501/11 , C12N2501/125 , C12N2501/148 , C12N2501/392
摘要： A process for the in vitro production of non-immortalised haematopoetic precursor cells of the erythroid line in which a population of erythroid precursor cells is exposed to a combination of growth factors containing a glucocorticoid and an oestrogen and at least one ligand of a tyrosine kinase receptor until the cells begin to renew themselves spontaneously.
-
公开(公告)号：EP1668132A1
公开(公告)日：2006-06-14
申请号：EP04764749.0
申请日：2004-09-02
发明人： WAERNER, Thomas , BEUG, Hartmut , JECHLINGER, Martin , GRUENERT, Stefan , TAMIR, Ido , KRAUT, Norbert , HEIDER, Karl-Heinz , SEITHER, Peter , WEITH, Andreas , ZOEPHEL, Andreas , KONOPITZKY, Renate , AHORN, Horst , JUNG, Birgit
IPC分类号： C12N15/19 , C07K14/52 , C12N15/11 , C07K16/24 , A61K31/70 , A61K39/395 , A61P17/02 , A61P35/00 , A61P35/04
CPC分类号： C12N15/1136 , A61K38/00 , C07K14/52
摘要： The functional characterization of ILEI to be a cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
-
公开(公告)号：EP0896543A1
公开(公告)日：1999-02-17
申请号：EP97916436.0
申请日：1997-04-04
CPC分类号： A61K39/3955 , A61K38/179
摘要： The invention concerns a drug containing as its active constituent a substance which inhibits the action of TGFβ on tumour cells of epithelial origin for the treatment of epithelial, invasive tumours characterized by a reversible transition of the cells from an epithelial, non-invasive state to a fibroblastic, invasive state. The drug contains a TGFβ inhibitor, preferably in combination with a Ras inhibitor. The invention also concerns a method of screening substances for the treatment of epithelial, invasive tumours.
-
公开(公告)号：EP0716689A1
公开(公告)日：1996-06-19
申请号：EP95925778.0
申请日：1995-06-28
IPC分类号： C12N5
CPC分类号： C12N5/0641 , C12N2501/11 , C12N2501/125 , C12N2501/148 , C12N2501/392
摘要： A process for the in vitro production of non-immortalised haematopoetic precursor cells of the erythroid line in which a population of erythroid precursor cells is exposed to a combination of growth factors containing a glucocorticoid and an oestrogen and at least one ligand of a tyrosine kinase receptor until the cells begin to renew themselves spontaneously.
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
